Supernus Pharmaceuticals (SUPN) Other Non-Current Assets (2011 - 2026)

Supernus Pharmaceuticals (SUPN) has 16 years of Other Non-Current Assets data on file, last reported at $56.5 million in Q1 2026.

• Other Non-Current Assets for Q1 2026 came in at $56.5 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $56.5 million (changed N/A YoY), and the FY2025 annual result was $63.8 million, changed N/A from the prior year.
• Other Non-Current Assets eased to $56.5 million in Q1 2026 per SUPN's latest filing, from $63.8 million in the prior quarter.
• Over five years, Other Non-Current Assets peaked at $403.8 million in Q1 2023 and troughed at $28.0 million in Q2 2025.
• A 5-year average of $72.6 million and a median of $41.3 million in 2022 frame the typical range for Other Non-Current Assets.
• The sharpest annual moves came in 2023 and 2024: Other Non-Current Assets jumped 724.23% in 2023, then plunged 90.5% in 2024.
• A 5-year view of Other Non-Current Assets shows it stood at $39.8 million in 2022, then retreated by 2.47% to $38.8 million in 2023, then declined by 7.55% to $35.9 million in 2024, then soared by 77.75% to $63.8 million in 2025, then fell by 11.51% to $56.5 million in 2026.
• Business Quant data shows SUPN's Other Non-Current Assets at $56.5 million in Q1 2026, $63.8 million in Q4 2025, and $62.4 million in Q3 2025.